메뉴 건너뛰기




Volumn 23, Issue 8, 2013, Pages 2384-2390

Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories

Author keywords

Allosteric MEK inhibitor; Blood brain barrier; Oncology; Structure based drug design

Indexed keywords

ALKYL ARYL ETHER; B RAF KINASE; ESTER; GLYCOPROTEIN; HYDROXAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; RAS PROTEIN; SULFANILAMIDE;

EID: 84875411534     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.02.028     Document Type: Article
Times cited : (14)

References (29)
  • 6
    • 46849116601 scopus 로고    scopus 로고
    • For an excellent compilation of allosteric MEK inhibitor patents until February 2008, see: S. Price Expert Opin. Ther. Patents 18 2008 603
    • (2008) Expert Opin. Ther. Patents , vol.18 , pp. 603
    • Price, S.1
  • 27
    • 79951722555 scopus 로고    scopus 로고
    • A close analog of JTP-70902 was later-on advanced to clinical development under the name GSK 1120212: see Ref. 7. For a more recently reported related series from Takeda, see
    • A close analog of JTP-70902 was later-on advanced to clinical development under the name GSK 1120212: see Ref. 7. For a more recently reported related series from Takeda, see: Q. Dong, D.R. Dougan, X. Gong, P. Halkowycz, B. Jin, T. Kanouni, S.M. O'Connell, N. Scorah, L. Shi, M.B. Wallace, and F. Zhou Bioorg. Med. Chem. Lett. 21 2011 1315
    • (2011) Bioorg. Med. Chem. Lett. , vol.21 , pp. 1315
    • Dong, Q.1    Dougan, D.R.2    Gong, X.3    Halkowycz, P.4    Jin, B.5    Kanouni, T.6    O'Connell, S.M.7    Scorah, N.8    Shi, L.9    Wallace, M.B.10    Zhou, F.11


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.